Salud financiera de hoja de balance de BioMarin Pharmaceutical
Salud financiera controles de criterios 6/6
BioMarin Pharmaceutical tiene un patrimonio de accionistas total de $5.1B y una deuda total de $1.1B, lo que sitúa su ratio deuda-patrimonio en 21.4%. Sus activos y pasivos totales son $6.9B y $1.8B respectivamente. El BAIT de BioMarin Pharmaceutical es de $189.5M, por lo que su ratio de cobertura de intereses es de -3.9. Tiene efectivo e inversiones a corto plazo que ascienden a $1.0B.
Información clave
21.4%
Ratio deuda-patrimonio
US$1.09b
Deuda
| Ratio de cobertura de intereses | -3.9x |
| Efectivo | US$1.05b |
| Patrimonio | US$5.07b |
| Total pasivo | US$1.80b |
| Activos totales | US$6.87b |
Actualizaciones recientes sobre salud financiera
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?
Feb 24Recent updates
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin: A Good Anchor For Your Biotech Portfolio
May 10BioMarin: Keep Waiting For The Growth
Mar 03BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?
Feb 24Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($3.0B) de BMRN superan a sus pasivos a corto plazo ($1.1B).
Pasivo a largo plazo: Los activos a corto plazo de BMRN ($3.0B) superan a sus pasivos a largo plazo ($711.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (0.8%) de BMRN se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de BMRN ha pasado de 28.4% a 21.4% en los últimos 5 años.
Cobertura de la deuda: La deuda de BMRN está bien cubierta por el flujo de caja operativo (25.8%).
Cobertura de intereses: BMRN gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.